Drug Manufacturing Stocks Rally Up to 89% in Six Months: Laurus Labs, Gland Pharma, Divi’s Laboratories and Piramal Pharma as Nifty Pharma Hits a Record on 9 November 2026
- November 13, 2026
- Posted by: Neeraj Pandey
- Category: News
6-month gains: Laurus Labs +88.64%, Gland Pharma +80.36%, Divi’s +72.35%, Piramal Pharma +38.65%. Nifty Pharma record 29,224.85 (9 Nov 2026), up about 27% in 2026.
Quick Answer
Four drug manufacturers have rallied sharply in six months: Laurus Labs by 88.64%, Gland Pharma by 80.36%, Divi’s Laboratories by 72.35% and Piramal Pharma by 38.65%. The Nifty Pharma index hit a record 29,224.85 on 9 November 2026 and is up about 27% this year, with contract manufacturers leading the surge. Jefferies and Choice Institutional Equities have positive views on Divi’s and Laurus. Rallies this large raise valuation and pullback risk, so investors should look at earnings and not only at price gains.
Drug manufacturing stocks have become one of the strongest pockets of the Indian market. A group of four companies, Laurus Labs, Gland Pharma, Divi’s Laboratories and Piramal Pharma, has delivered six-month gains of between 38.65% and 88.64%, and the Nifty Pharma index reached a record high of 29,224.85 on 9 November.
This article reviews the numbers, explains what is driving the CDMO theme, looks at what analysts say, compares valuation and flags the risks. Prices are from about 10 AM on 13 November 2026, and the six-month gains come from a report published by IndiaIPO. The rally in pharma stocks has been broad, though not equal.
Click Here – Get Free Investment Predictions
Six-Month Performance of the Four Stocks
| Stock | Six-month gain | Price (13 November, 10 AM) | Day move |
|---|---|---|---|
| Laurus Labs | 88.64% | Rs 2,435.00 | Up 1.46% |
| Gland Pharma | 80.36% | Rs 3,338.10 | Up 0.89% |
| Divi’s Laboratories | 72.35% | Rs 11,628.00 | Up 1.25% |
| Piramal Pharma | 38.65% | Rs 244.74 | Down 0.13% |
The spread between the best and worst performers is wide. Laurus Labs and Gland Pharma have more than 80% gains, while Piramal Pharma has risen about 39%. Strong performance in all four shows that the move is a sector theme and not a single-stock event. Pharma stocks in the group have moved together, which points to a sector theme.
Why Pharma Stocks Are Rallying
The Nifty Pharma index set a record high of 29,224.85 on 9 November and is up about 27% in 2026. It closed at 28,675.75 on 12 November, down 0.35%, which is about 1.9% below the peak, according to our own calculation. The pharma stock rally has therefore been underway for much of the year.
Contract development and manufacturing companies led the move. Divi’s, Laurus, Sai Life Sciences and Gland rose between 5% and 9% on 9 November. The CDMO model rewards companies that win long-term contracts for complex molecules, and customers have been spreading production across more suppliers. CDMO stocks have been the main beneficiaries of this focus on outsourcing.
What Analysts Say About the Sector
| Broker | Stock | Rating | Target |
|---|---|---|---|
| Jefferies | Divi’s Laboratories | Buy | Rs 12,550 |
| Choice Institutional Equities | Laurus Labs | Add | Rs 2,500 |
Jefferies pointed to CDMO revenue growth of about 50% in Q2 at Divi’s. Against the current price of Rs 11,628, the Jefferies target implies about 7.9% upside, and the Choice target for Laurus implies about 2.7% upside at Rs 2,435, both our own calculations. These small gaps show that much of the optimism is already in the prices.
Valuation and Quality: What to Check
A rally of 70% to 89% in six months moves a stock from fair value toward demanding value, so check the numbers behind the rise. Compare each company’s PE with its own history, review the growth in revenue and profit, look at the return on capital and see whether the order book supports future earnings.
| Check | Why it matters |
|---|---|
| Revenue and profit growth | The rally needs earnings growth to stay supported |
| Client concentration | Contracts with a few large customers raise risk |
| Plant inspection record | Regulatory findings can halt shipments |
| Capacity and capex | New capacity must be filled to protect returns |
| Valuation versus history | A high multiple leaves little room for a miss |
CDMO Stocks: Why Contract Manufacturing Is Attracting Money
CDMO stocks sit between drug developers and patients. A developer that does not want to build its own plant pays a CDMO to make the active ingredient or the finished product, often under multi-year contracts. Once a CDMO is qualified for a molecule, switching costs for the client are high, which gives revenue visibility.
That visibility is a large part of why CDMO stocks command premium multiples. The risk is that the premium depends on the contracts continuing, so a lost client or a delayed project can hit the share price hard.
What the Pharma Stock Rally Does Not Tell You
A pharma stock rally of this size tells you what has happened and not what will. Past returns do not predict future returns, and a sector at a record can mean either that growth is accelerating or that valuations have run ahead of earnings. The two explanations call for different actions, so the work is in checking the numbers.
For example, a stock that has doubled needs to grow earnings substantially just to keep its multiple. Investors should look at how much of the price gain came from earnings and how much from a higher multiple.
| Company | Business focus |
|---|---|
| Laurus Labs | Active ingredients, formulations and contract development and manufacturing |
| Gland Pharma | Injectable medicines and contract manufacturing |
| Divi’s Laboratories | Active ingredients and custom synthesis |
| Piramal Pharma | Contract manufacturing, complex hospital generics and consumer health |
Compare pharma and CDMO stocks on the Univest Screener
Risks Facing Drug Manufacturing Stocks
Regulatory inspections at manufacturing sites can lead to warning letters and import alerts. US drug pricing policy and tariff talk affect demand and margins, and currency moves change export earnings. Contract timing is also lumpy, so a quarter can be weak even when the long-term story is intact.
The sector is also crowded after the rally. When many investors hold the same winners, a negative surprise can lead to a quick fall, and profit booking after record highs is common.
Download the Univest iOS App or Univest Android App to track pharma stocks and set price alerts.
Conclusion
The rise in these CDMO and pharma stocks is backed by real demand for outsourced production and by a record in the Nifty Pharma index, but the gains of up to 89% in six months have used up some of the easy upside. Investors should study company earnings, client mix and regulatory records, and treat the six-month return as a warning to check valuation, not as a reason to chase.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which drug manufacturing stocks have rallied the most in six months?
Ans. According to a report on four drug manufacturers, Laurus Labs gained 88.64%, Gland Pharma 80.36%, Divi’s Laboratories 72.35% and Piramal Pharma 38.65% over six months. The headline figure of up to 89% refers to Laurus Labs, the best performer in the group.
Why are pharma stocks rising?
Ans. The Nifty Pharma index set a record high of 29,224.85 on 9 November 2026 and is up about 27% in 2026. Contract development and manufacturing companies, known as CDMOs, rose 5% to 9% on 9 November as investors bet on demand for outsourced drug production and for complex molecules. Stronger results also supported the rally.
What is a CDMO?
Ans. A contract development and manufacturing organisation makes drug ingredients and finished medicines for other pharmaceutical companies. Divi’s Laboratories, Laurus Labs, Sai Life Sciences and Gland Pharma are Indian examples. Their revenue depends on long-term client contracts and on capacity use in their plants.
What are analysts saying about these stocks?
Ans. Jefferies has a Buy rating on Divi’s Laboratories with a target of Rs 12,550, citing Q2 CDMO revenue growth of about 50%. Choice Institutional Equities has an Add rating on Laurus Labs with a target of Rs 2,500. Targets are opinions at a point in time and change as results arrive.
Are drug manufacturing stocks expensive after the rally?
Ans. Valuations have expanded with the prices, and the pharma index is at a record. Compare each company’s PE with its own history and with peers, and look at whether earnings growth justifies the multiple. A rally of 70% to 89% in six months also raises the risk of a pullback.
What are the risks for pharma and CDMO stocks?
Ans. Key risks include dependence on a few large clients, regulatory inspections at manufacturing sites, US pricing pressure, currency swings and the lumpy timing of contracts. After sharp rallies, stocks are also vulnerable to profit booking.
